Conference Correspondent

MURANO Study Explores Potential for Venetoclax-Rituximab Combination Therapy in Relapsed/Refractory CLL

Conference Correspondent - ASH 2018 - CLL

Researchers continue to focus on novel combination approaches in the treatment of chronic lymphocytic leukemia (CLL). In the phase 3 MURANO study, the efficacy and safety of venetoclax in combination with rituximab (VenR) in relapsed/refractory (R/R) CLL was evaluated as fixed-duration treatment compared with standard bendamustine + rituximab (BR). An initial analysis established a superior progression-free survival (PFS) of VenR over BR at median follow-up of 23.8 months (Seymour JF, et al. N Engl J Med. 2018). Here, researchers present longer-term outcome data with a median follow-up of 36 months.

Patients were randomized to receive 6 cycles of VenR followed by venetoclax 400 mg once daily for a maximum of 2 years, or 6 cycles of BR. In total, 389 patients were enrolled in the VenR (n = 194) and BR (n = 195) arms. In the VenR arm, 174 (90%) completed the VenR combination phase and 130 (67%) had completed 2 years of venetoclax treatment. For BR, 154 (79%) had completed 6 cycles.

With a median time of 9.9 months off venetoclax after 2 years of treatment, PFS with VenR remained superior to BR. Three-year PFS estimates were 71.4% for VenR versus 15.2% for BR, and 3-year overall survival estimates were 87.9% versus 79.5%, respectively. The treatment effect with VenR was consistent across subgroups, including age, number of prior regimens, and mutational status.

In terms of safety, the VenR regimen was well-tolerated, with no new safety signals. Notable grade 3/4 adverse events in the VenR arm (≥10%) included neutropenia (58.8%) and anemia (10.8%).

Researchers concluded that this study demonstrates clinically meaningful benefit of the VenR regimen in all patients with R/R CLL, with no new safety signals present.

Seymour JF, et al. ASH 2018. Abstract 184.

Related Items
Prognostic Testing and Treatment Approaches in Patients with CLL: Interim Analysis of the informCLL Real-World Registry
Conference Correspondent published on December 4, 2018 in ASH 2018 - CLL
Acalabrutinib in Patients with Relapsed/Refractory and High-Risk, Treatment-Naïve CLL
Conference Correspondent published on December 4, 2018 in ASH 2018 - CLL
Cost-Effectiveness Comparison of Ibrutinib, Chemotherapy, and Chemoimmunotherapy in First-Line Treatment of CLL
Conference Correspondent published on December 4, 2018 in ASH 2018 - CLL
ECOG-ACRIN Cancer Research Group: Phase 3 Study of Ibrutinib-Based Therapy in Untreated Younger Patients with CLL
Conference Correspondent published on December 4, 2018 in ASH 2018 - CLL
Ibrutinib Treatment in Waldenström’s Macroglobulinemia: Follow-Up Efficacy and Safety from the iNNOVATE Study
Conference Correspondent published on December 2, 2018 in ASH 2018 - CLL
Last modified: December 2, 2018
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME